Figure 4
Figure 4. Loss of membrane domain polarity in blast cells from leukemic patients. (A) Percentage of normal human CD34+ cells and leukemic blasts with membrane domain polarity. (B-I) Analysis of the cell cycling status (B,D,F,H), and membrane domain polarity (C,E,G,I) of normal human MPB CD34+ cells (B-C), and blast cells from patients with AML (D-E), CML (F-G), or ALL (H-I). (J) Percentage of human cell homing in NSG mice 16 hours after transplantation of control or MβCD-treated leukemic blasts (AML ▴, CML ●, AML/MDS ■, t test, P > .1). Scale bars in panels C, E, G, and I equal 5 μm. Horizontal bars in panels A and J represent means (*P < .0001).

Loss of membrane domain polarity in blast cells from leukemic patients. (A) Percentage of normal human CD34+ cells and leukemic blasts with membrane domain polarity. (B-I) Analysis of the cell cycling status (B,D,F,H), and membrane domain polarity (C,E,G,I) of normal human MPB CD34+ cells (B-C), and blast cells from patients with AML (D-E), CML (F-G), or ALL (H-I). (J) Percentage of human cell homing in NSG mice 16 hours after transplantation of control or MβCD-treated leukemic blasts (AML ▴, CML ●, AML/MDS ■, t test, P > .1). Scale bars in panels C, E, G, and I equal 5 μm. Horizontal bars in panels A and J represent means (*P < .0001).

Close Modal

or Create an Account

Close Modal
Close Modal